--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About ABUS20260320C3
Biological Technology
Arbutus Biopharma Corporation was incorporated in British Columbia on October 6, 2005. The Company is a clinical-stage biopharmaceutical company that leverages its extensive virology expertise to identify and develop novel therapies with unique mechanisms of action that can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (HBV) infection. The Company's pipeline of proprietary compounds developed in-house includes an RNA therapy drug imdusiran (AB-729) and an oral PD-L1 inhibitor AB-101. Imdusiran has produced meaningful clinical data demonstrating the effects on surface antigen reduction and reawakening of HBV-specific immune responses.
